Clinical trials: Elevated Low Density Lipoprotein Cholesterol
- Condition Elevated Low Density Lipoprotein Cholesterol
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hypercholesterolemia
Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol
Primary Objective: To assess the effects of subcutaneous (SC) doses of alirocumab on the elimination (measured by Fractional Clearance Rate (FCR)) of apolipoprotein B (apoB) in low density lipoprotein (LDL) in adults with mildly…
- Trial name
- NCT01959971
- Testing
- alirocumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Participants
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels
The purpose of this study is to evaluate pharmacodynamics (PD) of AZD0780 compared with placebo by assessment of low-density lipoprotein-cholesterol (LDL-C) levels following repeated oral dosing in healthy adults with elevated…
- Trial name
- NCT07423598
- Testing
- AZD0780
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypercholesterolemia, LDL Cholesterol
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
- Trial name
- NCT01859455
- Testing
- LGT209 50 mg, LGT209 300 mg, Statins (atorvastatin or simvastatin)
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Health
Effect of a Mixture of Allium Extracts on LDL Cholesterol Levels Volunteers With Elevated LDL Cholesterol Levels
To evaluate the efficacy of daily consumption of a combination of concentrated extracts of garlic (Allium sativum L.) and onion (Allium cepa L.) on LDL cholesterol levels in healthy volunteers.
- Trial name
- NCT04646382
- Testing
- Garlic and onion concentrate, Control
- Where
- Spain
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- DOMCA S.A.
Hyperlipidemias
A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered…
- Trial name
- NCT06239714
- Testing
- SGB-3403, Atorvastatin
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Hypercholesterolemia
Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol
Chitosan is a natural product that is produced commercially through the deacetylation of chitin, which is found in the exoskeleton of crustaceans. It has been suggested that chitosan has a lipid-lowering effect.
- Trial name
- HEP-40 (NCT00454831)
- Testing
- HEP-40 chitosan
- Where
- Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- DNP Canada
Inclisiran Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a…
- Trial name
- NCT07626281
- Testing
- Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
- Where
- 6 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hyperlipemia
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2053 when administered subcutaneously to subjects with normal and elevated LDL-C.
- Trial name
- NCT06229548
- Testing
- SYH2053
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Cardiovascular Diseases
Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format.
- Trial name
- NCT01200160
- Testing
- Niacin
- Where
- 22 sites in Colombia, Mexico and 1 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Abbott
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects
Objectives: The primary and secondary objectives of the study are presented below. Exploratory objectives are presented in the body of the protocol.
- Trial name
- NCT05905068
- Testing
- RN0191 INJECTION
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd
Healthy Volunteers
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body…
- Trial name
- NCT01618916
- Testing
- LY3015014
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Participants
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of LY2484595 much higher than what is needed for…
- Trial name
- NCT01448824
- Testing
- LY2484595, Ketoconazole
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy
- Trial name
- NCT03427710
- Testing
- CiVi007
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Civi Biopharma, Inc.
Elevated LDL-Cholesterol (LDL-C)
Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-PCS02 in subjects with Elevated LDL-Cholesterol (LDL-C).
- Trial name
- NCT01437059
- Testing
- ALN-PCS02, Sterile Normal Saline (0.9% NaCl)
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Hyperlipidemia
A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
This is a study in otherwise healthy Japanese and non-Japanese participants with elevated low density lipoprotein cholesterol (LDL-C).
- Trial name
- NCT01426412
- Testing
- LY3015014 IV, LY3015014 SC
- Where
- 3 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia, Healthy Volunteers
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
This is a single-center, randomized, double-blind, placebo-controlled, single HST101 SC dose cohort study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Chinese Participants with Elevated…
- Conditions
- Hypercholesterolemia, Healthy Volunteers, LDL-Cholesterol
- Trial name
- NCT06504043
- Testing
- HST101
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
Elevated LDL Cholesterol
Oat and Cholesterol
The primary objective is to assess the effect of an oat ingredient provided over 4 weeks on serum LDL cholesterol in men and women with elevated LDL-cholesterol compared to a placebo.
- Trial name
- NCT03911427
- Testing
- Active oat beverage, Control rice beverage
- Where
- Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Hypercholesterolemia
A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-PCSSC in subjects with elevated LDL-C.
- Trial name
- NCT02314442
- Testing
- ALN-PCSSC, Sterile Normal Saline (0.9% NaCl)
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Dyslipidemia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination…
- Trial name
- NCT05787002
- Testing
- AZD0780, Rosuvastatin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca